IN BRIEF: Hikma gets preliminary US approval for Custopharm acquisition

Wed, 20th Apr 2022 09:16

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injectable products company for a total of up to USD425 million.

Current stock price: 2,068.00 pence, down 0.6% on Wednesday

12-month change: down 13%

By Tom Budszus; tombudszus@alliancenews.com

Related Shares

More News

3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

26 Apr 2024 13:36

UK dividends calendar - next 7 days

25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth readi...

25 Apr 2024 10:15

Hikma Pharmaceuticals backs outlook after making strong start to 2024

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday reported an encouraging start to the year supported by all three business segments.

25 Apr 2024 08:01

Hikma delivers strong Q1, holds on to guidance

(Sharecast News) - Pharmaceuticals group Hikma said it has made a "strong and encouraging start" to 2024, with all three business segments performing ...